MannKind founder says inhaled insulin system could be 'blockbuster'

The company releases test results showing that its Technosphere insulin delivery system is as effective for diabetics as injections. But investors are still wary about safety; MannKind's stock slumps. Valencia biotechnology company MannKind Corp. thought it had encouraging news about its experimental insulin inhaler on Tuesday. But Wall Street wasn't buying it.

Read the whole article on LA Times - Science

More from LA Times - Science